Healios K.K.
HLOSF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$243M
Close$
$-0.28
115.6% downside
Current Fair Value
115.6% downsideOvervalued by 115.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $243.00 Million |
|---|---|
| Enterprise Value | $-6,262,996,580.00 |
| Earnings per Share | $-20.59 |
| Beta | 1.43 |
| Outstanding Shares | 135,001,900 |
Return
| Return on Equity | 2.35% |
|---|---|
| Return on Assets | 0.89% |
| Return on Invested Capital | -15.16% |
Valuation & Multiples
| P/E Ratio | 55.04 |
|---|---|
| PEG | -35.4 |
| Price to Sales | - |
| Price to Book Ratio | 0.03 |
| Enterprise Value to Revenue | 514.4 |
| Enterprise Value to EBIT | -10.6 |
| Enterprise Value to Net Income | -31 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.01
Consensus analyst estimateRevenue Estimate
$108,632
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.07
Consensus analyst estimateRevenue Estimate
$211,767
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Healios K.K.
75 employees
CEO: Tadahisa S. Kagimoto
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key ...